


DOCKET NO.: UNGR-1598



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Application of:

Evan C. Unger et al.

Serial No.: 09/699,679

Filing Date: October 30, 2000

For: NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND
THERAPEUTIC USE

Confirmation No.: 8248

Group Art Unit: 1617

Examiner: Shahnam J. Sharareh

EXPRESS MAIL LABEL NO: EV 160093529 US
DATE OF DEPOSIT: April 10, 2003

Assistant Commissioner for Patents
Washington DC 20231

Sir:

AMENDMENT

This amendment is being submitted in response to the Office Action dated March 12, 2003 issued in connection with the above-identified application. Applicants respectfully request entry of the following amendment, without prejudice.

IN THE SEQUENCE LISTING:

Please insert pages 1 to 7 of the Substitute Sequence Listing submitted herewith.

REMARKS

Applicants request entry of pages 1 to 7 of the substitute sequence listing submitted herewith. The sequence listing has been amended to explain the genetic source of the sequences. As the sequence listing is supported by the application as filed, no new matter is